

Triage of women with ASC-US/LSIL cytology: The added value of implementation of an HPV-test



Msomphora MR, Sørbye SW, Gutteberg TJ, Skjeldestad FE

Faculty of Health Sciences, University of Tromsø, Norway, and University Hospital of North Norway, Tromsø, Norway

Background

Within the Norwegian cervical cancer screening program women were recommended biopsy after three consecutive smears of minor lesions (ASC-US/LSIL) 6-12 months apart until 2005. In 2005 the recommendations for biopsy changed to the 2nd ASC-US/LSIL, if the HPV-test was positive.




Figure 1. Flow-chart indicating the guidelines for follow-ups during first study period 1996 – 1998.




Figure 2. Flow-chart indicating the guidelines for follow-ups during second study period 2006 – 2008. (Source: Sørbye SW et al. 2010)

Objective

To determine the outcomes of secondary cervical cancer screening in two time-periods before (1996-1998) and after (2006-2008) implementation of an HPV test

Materials and methods

This study has an historical prospective design by including in retrospect all screening- and follow-up tests for women aged 25 to 69 years old kept by the Department of Clinical Pathology, University Hospital of Northern Norway, Tromsø.

All women with a first ASC-US/LSIL smear in 1996-98 and 2006-08 were identified and compared on outcomes such as proportion of cases resolved within 35 months of index smear and incidence of CIN2+.

The Department of Clinical pathology has used an mRNA test (NorChip PreTect HPV-Proofer) since the autumn of 2005 in secondary cervical cancer screening.

Conclusion

Study period	Number of cases	Average time taken to biopsy
1996 – 1998	125	24 (23,8 ≈ 24) Months
2006 – 2008	41	12 (11,7 ≈ 12) Months

In triage of women with ASC-US/LSIL, the HPV mRNA test significantly reduced the time from the first abnormal cytology until biopsy and had predictive values comparable with those of repeat cytology

Results

- In 1996-98 and 2006-08 our laboratory processed 89 781 and 70 433 smears, respectively, in which periods 1733 and 1148 first diagnosis ever of ASC-US/LSIL were diagnosed among women 25 through 69 years of age.
- In 2006-08 744 of 1148 eligible women had a valid HPV-test and comprise the study population in this study period.
- In these subsets 14.6% (253/1733) in 1996-98 and 10.4% (77/744) in 2006-08 of the women were eligible for colposcopy/biopsy according to national screening recommendations.
- In 2006-08, when the HPV mRNA test was applied, the mean time to resolve an ASC-US/LSIL was 12 months (range 1-39) relative 24 months (range 1-146) in 1996-98 ($p < 0,01$).
- There were no differences in the biopsy rate in women recommended colposcopy (49.4% versus 53.2%), nor the positive predictive value of CIN2+ 67.2% (84/124) versus 68.3% (28/41) over the time-periods.